Table 3. Univariate analysis of 5 year survival rates after hyperthermo-chemoradiotherapy (HRCT).

Factors	N (%)	OS		LC		DMFS
		Rate (%)	P-value	Rate (%)	P-value	Rate (%)	P-value
Age
<60	27 (35)	85	0.32	93	0.65	78	0.95
≥60	51 (65)	77		90		80
Gender
Male	55 (71)	78	0.66	87	0.08	82	0.49
Female	23 (30)	83		100		74
Clinical stage
1	4 (5)	100	0.55	75	0.19	100	0.63
2	18 (23)	72		83		78
3	56 (80)	80		95		79
HLA (Pre-HCRT)
Grade 0, 1	77 (99)	79	0.56	91	0.73	81	0.06
Grade 2, 3	1 (1)	100		100		0
HLA (Post-HCRT)
Grade 0, 1	33 (64)	76	0.60	94	0.86	76	0.63
Grade 2, 3	19 (37)	79		74		79
Pathological effect
pCR	26 (33)	85	0.42	100	<0.05	85	0.55
No pCR	52 (67)	77		87		77

OS, overall survival; LC, local control; DMFS, distant metastasis-free survival; HLA, human leukocyte antigen.